×
0 0 0 0 0.00176444640494041 -0.0110277900308778 0.0172033524481693 -0.00485222761358637
Stockreport

Cellectis shares slump as death puts cell therapy tests on hold [Reuters (UK)]

CELLECTIS SA AMERICAN DEPOSI (CLLS)  More Company Research Source: Reuters
Last cellectis sa american deposi earnings: 8/1 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF Cellectis shares slump as death puts cell therapy tests on hold | Reuters 3 Min Read LONDON (Reuters) - French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis’s recently approved Kymriah, has been forced to suspend testing following a patient death. Cellectis said on Tuesday it was working closely with the U.S. Food and Drug Administration in order to resume trials with a lower dose of the medicine UCART123. Shares in the company fell 26 percent in morning trade following the U.S. regulator’s decision to place a so-called clinical hold on two early-stage trials of the medicine in blood cancers. Novartis made history last week when it won approval for its $475,000 drug Kymriah, the first in a new class of treatments called CAR-T immunotherapies that use modified disease-fighting T cells to attack cancer. While Novartis and rivals such as Juno and Kite use cells from the patient’s own body, Cellectis’s gene edited cell therapy [Read more]

IMPACT SNAPSHOT EVENT TIME: CLLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CLLS alerts

from News Quantified
Opt-in for
CLLS alerts

from News Quantified